Validation of the Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12)

David T Eton, David Cella, Susan E. Yount, Kimberly M. Davis

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We tested the reliability and validity of a brief symptom index for use with patients in the advanced stages of lung cancer. The Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12) is a brief self-report measure that combines seven items addressing symptoms common in advanced-stage lung cancer with five symptoms or concerns that are relevant to most people with advanced-stage cancer. The index was administered prospectively to 92 advanced-stage lung cancer patients beginning at the initiation of chemotherapy and for 12 consecutive weeks. Reliability, convergent and concurrent validities, and responsiveness to change were determined and a minimally important difference (MID) was estimated. The index had good internal consistency (all Cronbach's α's > 0.70), moderate to high item-to-total correlations (93% ρ's ≥ 0.30), and correlated highly with a measure of overall quality of life (ρ's ≥ 0.50). Baseline scores differentiated patients with better versus worse clinical features (p's < .05). Prospective changes in index scores were sensitive to changes in performance status ratings (p's < .05). An MID of 3-4 points was estimated by combining guideline-, distribution-, and anchor-based methods. The results show that the FLSI-12 is a psychometrically sound measure and support its use as an endpoint in clinical trials of advanced-stage lung cancer.

Original languageEnglish (US)
Pages (from-to)339-347
Number of pages9
JournalLung Cancer
Volume57
Issue number3
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Lung Neoplasms
Therapeutics
Reproducibility of Results
Self Report
Quality of Life
Clinical Trials
Guidelines
Drug Therapy
Neoplasms

Keywords

  • FACT
  • FLSI-12
  • Lung cancer
  • Minimally important difference
  • Patient-reported outcome
  • Quality of life
  • Symptoms
  • Validity

ASJC Scopus subject areas

  • Oncology

Cite this

Validation of the Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12). / Eton, David T; Cella, David; Yount, Susan E.; Davis, Kimberly M.

In: Lung Cancer, Vol. 57, No. 3, 09.2007, p. 339-347.

Research output: Contribution to journalArticle

Eton, David T ; Cella, David ; Yount, Susan E. ; Davis, Kimberly M. / Validation of the Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12). In: Lung Cancer. 2007 ; Vol. 57, No. 3. pp. 339-347.
@article{aced2f3b85624de0a4a509ec7a73b1d1,
title = "Validation of the Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12)",
abstract = "We tested the reliability and validity of a brief symptom index for use with patients in the advanced stages of lung cancer. The Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12) is a brief self-report measure that combines seven items addressing symptoms common in advanced-stage lung cancer with five symptoms or concerns that are relevant to most people with advanced-stage cancer. The index was administered prospectively to 92 advanced-stage lung cancer patients beginning at the initiation of chemotherapy and for 12 consecutive weeks. Reliability, convergent and concurrent validities, and responsiveness to change were determined and a minimally important difference (MID) was estimated. The index had good internal consistency (all Cronbach's α's > 0.70), moderate to high item-to-total correlations (93{\%} ρ's ≥ 0.30), and correlated highly with a measure of overall quality of life (ρ's ≥ 0.50). Baseline scores differentiated patients with better versus worse clinical features (p's < .05). Prospective changes in index scores were sensitive to changes in performance status ratings (p's < .05). An MID of 3-4 points was estimated by combining guideline-, distribution-, and anchor-based methods. The results show that the FLSI-12 is a psychometrically sound measure and support its use as an endpoint in clinical trials of advanced-stage lung cancer.",
keywords = "FACT, FLSI-12, Lung cancer, Minimally important difference, Patient-reported outcome, Quality of life, Symptoms, Validity",
author = "Eton, {David T} and David Cella and Yount, {Susan E.} and Davis, {Kimberly M.}",
year = "2007",
month = "9",
doi = "10.1016/j.lungcan.2007.03.021",
language = "English (US)",
volume = "57",
pages = "339--347",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Validation of the Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12)

AU - Eton, David T

AU - Cella, David

AU - Yount, Susan E.

AU - Davis, Kimberly M.

PY - 2007/9

Y1 - 2007/9

N2 - We tested the reliability and validity of a brief symptom index for use with patients in the advanced stages of lung cancer. The Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12) is a brief self-report measure that combines seven items addressing symptoms common in advanced-stage lung cancer with five symptoms or concerns that are relevant to most people with advanced-stage cancer. The index was administered prospectively to 92 advanced-stage lung cancer patients beginning at the initiation of chemotherapy and for 12 consecutive weeks. Reliability, convergent and concurrent validities, and responsiveness to change were determined and a minimally important difference (MID) was estimated. The index had good internal consistency (all Cronbach's α's > 0.70), moderate to high item-to-total correlations (93% ρ's ≥ 0.30), and correlated highly with a measure of overall quality of life (ρ's ≥ 0.50). Baseline scores differentiated patients with better versus worse clinical features (p's < .05). Prospective changes in index scores were sensitive to changes in performance status ratings (p's < .05). An MID of 3-4 points was estimated by combining guideline-, distribution-, and anchor-based methods. The results show that the FLSI-12 is a psychometrically sound measure and support its use as an endpoint in clinical trials of advanced-stage lung cancer.

AB - We tested the reliability and validity of a brief symptom index for use with patients in the advanced stages of lung cancer. The Functional Assessment of Cancer Therapy-Lung Symptom Index-12 (FLSI-12) is a brief self-report measure that combines seven items addressing symptoms common in advanced-stage lung cancer with five symptoms or concerns that are relevant to most people with advanced-stage cancer. The index was administered prospectively to 92 advanced-stage lung cancer patients beginning at the initiation of chemotherapy and for 12 consecutive weeks. Reliability, convergent and concurrent validities, and responsiveness to change were determined and a minimally important difference (MID) was estimated. The index had good internal consistency (all Cronbach's α's > 0.70), moderate to high item-to-total correlations (93% ρ's ≥ 0.30), and correlated highly with a measure of overall quality of life (ρ's ≥ 0.50). Baseline scores differentiated patients with better versus worse clinical features (p's < .05). Prospective changes in index scores were sensitive to changes in performance status ratings (p's < .05). An MID of 3-4 points was estimated by combining guideline-, distribution-, and anchor-based methods. The results show that the FLSI-12 is a psychometrically sound measure and support its use as an endpoint in clinical trials of advanced-stage lung cancer.

KW - FACT

KW - FLSI-12

KW - Lung cancer

KW - Minimally important difference

KW - Patient-reported outcome

KW - Quality of life

KW - Symptoms

KW - Validity

UR - http://www.scopus.com/inward/record.url?scp=34548104676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548104676&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.03.021

DO - 10.1016/j.lungcan.2007.03.021

M3 - Article

C2 - 17485135

AN - SCOPUS:34548104676

VL - 57

SP - 339

EP - 347

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -